FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Flat FDA Budget Moves Through Senate Subcommittee
07/19/2017
 
 
TXT Gottlieb Selects 2 More for his Leadership Team
07/20/2017
 
 
TXT Groups Still Oppose ‘Intended Use’ Final Rule
07/19/2017
 
 
TXT 14 Intas Pharmaceutical Inspection Observations
07/20/2017
 
 
TXT Supply Chain Security Toolkit Out
07/20/2017
 
 
TXT FDA Researching ‘Fair Balance’ with DTC Tweets, Etc.
07/17/2017
 
 
TXT FDA REMS Standards Need Assessment
07/17/2017
 
 
TXT Gottlieb Tells More on on Generic Drug Policy Relief
07/19/2017
 
 
TXT DoJ Views on ‘Responsible Executive’ Prosecutions
07/18/2017
 
 
TXT Guidance on IRB Waivers in Certain Scenarios
07/24/2017
 
 
TXT FDA Releases Revised ICH Efficacy Format Guidance
07/24/2017
 
 
TXT House Hearing on Antitrust Issues Related to FDA Approval Process
07/24/2017
 
 
TXT Product Approval Summaries
07/23/2017
 
 
TXT Latest Federal Register Notices
07/23/2017
 
 
TXT Since Our Last Issue ...
07/23/2017
 
 
TXT Former FDAer Horowitz Joins Hogan Lovells
07/21/2017
 
 
TXT Penumbra Recalls 3D Revascularization Device
07/21/2017
 
 
TXT Fujifilm Recalls Duodenoscopes to Correct Safety Issues
07/21/2017
 
 
TXT Soft Tissue Filler Approvals Can be Strengthened: Researchers
07/20/2017
 
 
TXT Med Prep Execs Guilty of Cancer Drug Contamination
07/20/2017
 
 
TXT Extended Use Date on Another Pfizer Product
07/19/2017
 
 
TXT National Biological Has QS Violations
07/18/2017
 
 
TXT CGMP Violations in Tubilux Inspection
07/18/2017
 
 
TXT Latest FDA Warning Letters
07/18/2017
 
 
TXT Gottlieb Moves to Overcome Hundreds of Scientific Vacancies
07/17/2017
 
 
TXT CDER Revises Policy on Posting Approval Info
07/17/2017
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving